Indirect comparison of anti‐interleukin 17 targeted biological treatments for moderate‐to‐severe psoriasis

Acedo, Rocío Díaz; Galván-Banqueri, Mercedes; Saavedra, Esther Márquez

doi:10.1111/jcpt.13153

Cited by 6 publications

(4 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The data on effectiveness is in line with the few indirect comparisons in the literature. 1,6 The same consideration can be made on the quality of life with brodalumab, achieving DLQI 0/1 more frequently than the other two treatments, although with only 51 patients observed. Different mean PASI at baseline among the treatments limits the evidence on achievement of PASI <3 at earlier time points, and the analysis of observed cases reduces the strength of evidence.…”

Section: Comparison Between Brodalumab Secukinumab and Ixekizumab Eff...mentioning

confidence: 99%

“…Dear Editor, Psoriasis is an inflammatory skin disease with an important impact worldwide; its treatment comprises biological therapies targeting specific immune cytokines, such as interleukin-17. 1,2 Three molecules targeting this cytokine have been used over the years. Differences in pharmacodynamics and pharmacokinetics are responsible for differences in therapeutic efficacy.…”

Section: Comparison Between Brodalumab Secukinumab and Ixekizumab Eff...mentioning

confidence: 99%

See 1 more Smart Citation

Comparison between brodalumab, secukinumab and ixekizumab effectiveness and drug survival: A real‐life experience on 638 patients with psoriasis

Mastorino

Cariti

Susca

et al. 2023

Experimental Dermatology

View full text Add to dashboard Cite

Section: Comparison Between Brodalumab Secukinumab and Ixekizumab Eff...mentioning

confidence: 99%

Section: Comparison Between Brodalumab Secukinumab and Ixekizumab Eff...mentioning

confidence: 99%

Comparison between brodalumab, secukinumab and ixekizumab effectiveness and drug survival: A real‐life experience on 638 patients with psoriasis

Mastorino

Cariti

Susca

et al. 2023

Experimental Dermatology

View full text Add to dashboard Cite

“…We included 47 NMAs assessing systemic treatments in moderate‐to‐severe psoriasis 18–64 . The publication rate grew from one published per year in 2006 to a maximum of 12 per year in 2020 (Figure 2).…”

Section: Resultsmentioning

confidence: 99%

Overlapping network meta‐analyses on psoriasis systemic treatments, an overview: quantity does not make quality

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Brodalumab is a human monoclonal antibody that binds to the IL-17 receptor A, thereby blocking the signalling of several IL-17-family cytokines [IL-17A, IL-17C, IL-17E (IL-25), IL-17F and IL17A/F], which may yield a more complete suppression of the inflammatory process in the skin [ 5 – 7 ]. Meta-analyses of randomised clinical trials (RCTs) and real-world studies indirectly comparing the effectiveness of the IL-17 inhibitors suggest a comparable or even favourable effectiveness of brodalumab [ 8 – 12 ]. Moreover, both direct and indirect comparisons suggest that brodalumab has a faster onset of action than other biologics[ 13 , 14 ].…”

Section: Introductionmentioning

confidence: 99%

Single-Centre Real-World Study on Drug Survival and Effectiveness of Brodalumab for Treatment of Psoriasis and Psoriatic Arthritis

2023

View full text Add to dashboard Cite

Background Clinical trials have established the efficacy of brodalumab in treatment of psoriasis and psoriatic arthritis. Real-world evidence is needed to fully evaluate the drug. Objective Here we investigate drug survival and clinical effectiveness of brodalumab in patients with psoriasis and psoriatic arthritis in a real-world setting. Methods This was a retrospective single-centre study enrolling patients receiving brodalumab for psoriasis at the Department of Dermatology, Aarhus University Hospital, Denmark. The primary endpoints were drug survival, reasons for discontinuation, percentage of patients achieving a Psoriasis Area and Severity Index (PASI) ≤ 2 and clinical effectiveness against psoriatic arthritis. Results Eighty-three patients were included (mean age 49.2 ± 17.4 years, 59.0% male, 9.6% bio-naïve, mean baseline PASI 10.9 ± 6.9). Twenty-seven patients discontinued treatment primarily due to ineffectiveness and adverse events (AEs). Kaplan–Meier-estimated 1-year drug survival was 65.7%. An absolute Psoriasis Area and Severity Index (PASI) ≤ 2 was achieved by 68.2% of patients at end of follow-up, by 70.0% at weeks 12–17 and by 76.2% after 40–60 weeks of treatment. Neither drug survival nor PASI ≤ 2 was associated with baseline PASI ≥ 10, body mass index ≥ 30, previous treatment with > 2 biologics or other IL-17 inhibitors in particular ( P > 0.05). Psoriatic arthritis remission or partial remission was achieved by 10 out of 18 patients with psoriatic arthritis; treatment failure was reported in 5 patients. Conclusions Brodalumab was effective against psoriasis and psoriatic arthritis in a real-world setting. The drug survival was lower than reported in other real-world settings.

show abstract

Indirect comparison of anti‐interleukin 17 targeted biological treatments for moderate‐to‐severe psoriasis

Cited by 6 publications

References 14 publications

Comparison between brodalumab, secukinumab and ixekizumab effectiveness and drug survival: A real‐life experience on 638 patients with psoriasis

Comparison between brodalumab, secukinumab and ixekizumab effectiveness and drug survival: A real‐life experience on 638 patients with psoriasis

Overlapping network meta‐analyses on psoriasis systemic treatments, an overview: quantity does not make quality

Single-Centre Real-World Study on Drug Survival and Effectiveness of Brodalumab for Treatment of Psoriasis and Psoriatic Arthritis

Contact Info

Product

Resources

About